From traditional LAT to stereotactic radiotherapy: Evolving options for metastatic soft tissue sarcoma

Soft tissue sarcomas (STS) are rare and aggressive tumors with limited treatment options. A recent study by Burkhard-Meier et al. highlights Local Ablative Therapy (LAT) as a promising approach for metastatic STS, particularly pulmonary metastasectomy, which showed the best survival outcomes. Smaller tumors and longer treatment-free intervals were key predictors of success. Combining LAT with systemic therapy further improved progression-free survival. Advancements in stereotactic body radiation therapy (SBRT) offer potential benefits for STS, though data remains limited. While SBRT has shown success in breast and lung cancers, its role in STS requires further research. Until more trials confirm its efficacy, traditional LAT remains the preferred approach for carefully selected patients.